

Debra Moorman Hoppensteadt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2080107/publications.pdf>

Version: 2024-02-01

296
papers

1,356
citations

471061

17
h-index

454577

30
g-index

299
all docs

299
docs citations

299
times ranked

1838
citing authors

#	ARTICLE	IF	CITATIONS
1	Feasibility and preliminary efficacy of acupuncture for angina in an underserved diverse population. <i>Acupuncture in Medicine</i> , 2022, 40, 152-159.	0.4	2
2	Arterial-renal Syndrome in Patients with ESRD, a New Disease Paradigm. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962110728.	0.7	3
3	Dysregulation of Biomarkers of Hemostatic Activation and Inflammatory Processes are Associated with Adverse Outcomes in Pulmonary Embolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962110648.	0.7	2
4	The Relevance of Anti-PF4 Antibody Isotypes and Endogenous Glycosaminoglycans and their Relationship with Inflammatory Biomarkers in Pulmonary Embolism Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962210917.	0.7	4
5	Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962210999.	0.7	2
6	Molecular and cellular pathogenesis of endothelial lining in atrial fibrillation. <i>FASEB Journal</i> , 2022, 36, .	0.2	0
7	Thrombo-inflammatory Biomarkers in Patients with End-Stage Renal Disease. <i>FASEB Journal</i> , 2022, 36, .	0.2	0
8	Collagen Remodeling Proteins, Inflammatory Biomarkers and FABP Regulation in Understanding the Pathogenesis of Atrial Fibrillation. <i>FASEB Journal</i> , 2022, 36, .	0.2	0
9	Bioequivalence of Potency Adjusted Approved Heparin Solutions Compared to a Newly Developed Heparin Solution. <i>FASEB Journal</i> , 2022, 36, .	0.2	0
10	Oxidative Stress Biomarkers in Patients with End Stage Renal Disease. <i>FASEB Journal</i> , 2022, 36, .	0.2	0
11	Quantitative TFPI Antigen Release and Functionality After Intravenous Administration of Heparins Sourced From Various Species in Non-human Primates. <i>FASEB Journal</i> , 2022, 36, .	0.2	0
12	USP Potency Adjusted Bovine Mucosal Heparins are Comparable to Porcine Mucosal Heparin and May be Interchangeable for Anticoagulation. <i>FASEB Journal</i> , 2022, 36, .	0.2	0
13	Predictive Role of Blood Cellular Indices and Their Relationship with Endogenous Glycosaminoglycans as Determinants of Inflammatory Biomarkers in Pulmonary Embolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962211048.	0.7	2
14	Regulation of Cortisol in Patients Undergoing Total Joint Arthroplasty. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962198761.	0.7	0
15	Biomarkers of Platelet Activation and Their Prognostic Value in Patients With Sepsis-Associated Disseminated Intravascular Coagulopathy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962094330.	0.7	17
16	Interrelationship of MMP-9, Proteoglycan-4, and Inflammation in Osteoarthritis Patients Undergoing Total Hip Arthroplasty. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962199556.	0.7	7
17	Upregulation of Inflammatory Cytokines in Pulmonary Embolism Using Biochip-Array Profiling. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110131.	0.7	12
18	The Role of IL-13, IL-15 and Granulysin in the Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962095083.	0.7	9

#	ARTICLE	IF	CITATIONS
19	Biomarkers of Thrombo-Inflammatory Responses in Pulmonary Embolism Patients With Pre-Existing Versus New-Onset Atrial Fibrillation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110149.	0.7	2
20	Biomarkers, inflammation, and thrombosis in Hepatocellular Carcinoma. <i>FASEB Journal</i> , 2021, 35, .	0.2	0
21	Biomarkers of Inflammation and Thrombosis in Patients Undergoing Total Joint Replacement. <i>FASEB Journal</i> , 2021, 35, .	0.2	0
22	Quantification of Bovine and Porcine Heparins Utilizing the Heparin Red Assay, Applications in the Study of Pharmacokinetics and Pharmacodynamics. <i>FASEB Journal</i> , 2021, 35, .	0.2	0
23	Comparison of Functional Methods with Absolute Quantitation of Heparin Levels in Clinical Samples as measured by Heparin Red Assay. <i>FASEB Journal</i> , 2021, 35, .	0.2	0
24	A Multicenter Evaluation of a Point-of-Care Blood Glucose Meter System in Critically Ill Patients. <i>journal of applied laboratory medicine</i> , The, 2021, 6, 820-833.	0.6	11
25	Protamine Sulfate Neutralization Profile of Various Dosages of Bovine, Ovine and Porcine UFHs and Their Depolymerized Derivatives in Non-Human Primates. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110055.	0.7	2
26	The Relationship Between Thrombo-Inflammatory Biomarkers and Cellular Indices of Inflammation in Lymphoma Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110503.	0.7	0
27	Fibrinolytic Dysregulation Contributes to the Hypercoagulable State in Pulmonary Embolism Patients. <i>Blood</i> , 2021, 138, 3177-3177.	0.6	0
28	USP Standardized Mixtures of Bovine, Ovine and Porcine Heparin Exhibit Comparable Biologic Effects to Referenced Single Sourced Heparins and May be Interchangeable,. <i>Blood</i> , 2021, 138, 1067-1067.	0.6	3
29	Comparative Studies on the Anticoagulant Profile of Branded Enoxaparin and a New Biosimilar Version. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962096082.	0.7	2
30	Comparative Anticoagulant and Thrombin Generation Inhibitory Profile of Heparin, Sulodexide and Its Components. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962095491.	0.7	5
31	Effect of a Recombinant Human Soluble Thrombomodulin on Baseline Coagulation Biomarker Levels and Mortality Outcome in Patients With Sepsis-Associated Coagulopathy. <i>Critical Care Medicine</i> , 2020, 48, 1140-1147.	0.4	34
32	Studies on Tissue Factor Pathway Inhibitor Antigen Release by Bovine, Ovine and Porcine Heparins Following Intravenous Administration to Non-Human Primates. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962095185.	0.7	2
33	P1077PERSISTENCE OF CIRCULATING RESIDUAL HEPARIN IN ESRD PATIENTS UNDERGOING MAINTENANCE HEMODIALYSIS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
34	P1403PLASMA OSTEOPOINTIN LEVELS DIRECTLY CORRELATE WITH INTACT PARATHYROID HORMONE AND ALKALINE PHOSPHATE LEVELS IN END STAGE RENAL DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
35	Procalcitonin as a Marker of Comorbid Atrial Fibrillation in Chronic Kidney Disease and History of Sepsis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962093222.	0.7	4
36	Development of an Algorithm to Predict Mortality in Patients With Sepsis and Coagulopathy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962090284.	0.7	5

#	ARTICLE	IF	CITATIONS
37	Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios Predict All-Cause Mortality in Acute Pulmonary Embolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602961990054.	0.7	30
38	Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602961989512.	0.7	13
39	Vascular endothelial growth factor in bipolar depression: A potential biomarker for diagnosis and treatment outcome prediction. <i>Psychiatry Research</i> , 2020, 284, 112781.	1.7	13
40	Interrelationship of Osteopontin, MMP-9 and ADAMTS4 in Patients With Osteoarthritis Undergoing Total Joint Arthroplasty. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962096486.	0.7	15
41	Thrombin Generation Profile in Various Lymphoma Sub-Groups and Its Augmentation by Andexanet Alfa. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962098346.	0.7	1
42	Differential Augmentation of Thrombin Generation by Andexanet Alfa in Lymphoma Patients. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
43	Profiling of Inflammatory Biomarkers and Coagulation Factors in End-Stage Renal Disease. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
44	Altered Coagulation Parameters and D-Dimer Measurements in Sepsis are useful in Scoring the Risk Stratification. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
45	Discordance between the neutralization profile of apixaban, betrixaban, edoxaban and rivaroxaban in the clotting assays and anti-Xa measurements. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
46	Decreased Thrombin Generation Potential in Lymphoma Patients is associated with Increased D-dimer, CRP, vWF and TNF- α . Interrelationship between Thrombogenesis and Inflammation. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
47	Biological and Pharmacological Profiling of Pentosan Polysulfate (PPS) in Comparison to Heparin and its Relative Neutralization by Protamine Sulfate. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
48	Molecular Pathogenesis of Bone Degenerative Disease and Associated Inflammatory Processes. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
49	Studies on the Interaction of Unfractionated Heparin and Sulodexide with Functional Antiheparin Platelet Factor 4 Antibodies as Studied in Platelet Aggregation Assays. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
50	Heparinox, a generic version of low molecular weight heparin enoxaparin, is bioequivalent to the branded version. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
51	Assay Dependent Reversal of the Oral and Parenteral Anti-Xa Agents By Andexanet Alfa. <i>Blood</i> , 2020, 136, 39-40.	0.6	0
52	Validation of the Bioequivalence of USP Potency Adjusted Porcine, Ovine, and Bovine Heparins. <i>Blood</i> , 2020, 136, 6-6.	0.6	0
53	Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961986349.	0.7	18
54	Endothelial Dysfunction Is Associated with Mortality and Severity of Coagulopathy in Patients with Sepsis and Disseminated Intravascular Coagulation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961985216.	0.7	40

#	ARTICLE	IF	CITATIONS
55	Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961984752.	0.7	19
56	Comparison of Low-Molecular-Weight Heparins Prepared From Ovine Heparins With Enoxaparin. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961984070.	0.7	8
57	Markers of Inflammation and Infection in Sepsis and Disseminated Intravascular Coagulation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961984333.	0.7	60
58	Matrix Metalloproteinases and Their Inhibitors and Proteoglycan 4 in Patients Undergoing Total Joint Arthroplasty. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961982811.	0.7	14
59	Comparative Pharmacological Profiles of Various Bovine, Ovine, and Porcine Heparins. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961988940.	0.7	12
60	Chemometric analysis of porcine, bovine and ovine heparins. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 164, 345-352.	1.4	16
61	Biomarkers of Hemostatic Activation and Inflammation Are Associated with Altered Coagulation Parameters in Sepsis Patients. <i>Blood</i> , 2019, 134, 2401-2401.	0.6	1
62	Comparative Studies on the Interaction of Unfractionated Heparin and Sulodexide with Functional Anti-Heparin Platelet Factor 4 Antibodies. <i>Blood</i> , 2019, 134, 2446-2446.	0.6	1
63	Acupuncture to Improve Symptoms for Stable Angina: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2019, 8, e14705.	0.5	6
64	Differential Neutralization of Unfractionated Heparin, Enoxaparin and Fondaparinux by Andexanet Alpha. <i>FASEB Journal</i> , 2019, 33, 819.12.	0.2	0
65	A Generic Recombinant Factor VIIa is Comparable to the Branded Novoseven in In Vitro and Pharmacokinetic Studies in Primates. <i>FASEB Journal</i> , 2019, 33, 515.4.	0.2	0
66	A Factor Xa Inhibitor Antidote (andexanet alfa) is Capable of Neutralizing the Anticoagulant Effects of Unfractionated Heparin of Bovine, Ovine and Porcine Origin in a Comparable Manner as Protamine Sulfate. <i>FASEB Journal</i> , 2019, 33, lb37.	0.2	0
67	Coagulation and Circulating Heparin Profile in Patients with End Stage Renal Disease Undergoing Maintenance Hemodialysis. <i>FASEB Journal</i> , 2019, 33, lb406.	0.2	0
68	Ovine Mucosal Enoxaparin Exhibit Comparable Pharmacokinetic Profiles to Porcine Mucosal Enoxaparin. <i>FASEB Journal</i> , 2019, 33, 515.12.	0.2	0
69	Comparative Studies on the Oral Anticoagulant Activities of Orally Active Anti-Xa and Anti-IIa Agents in Whole Blood and Plasma and their Neutralization by FEIBA. <i>FASEB Journal</i> , 2019, 33, 515.2.	0.2	0
70	A Comparison of GMP Manufactured Ovine Mucosal Enoxaparin and Branded Porcine Enoxaparin. <i>FASEB Journal</i> , 2019, 33, 515.11.	0.2	0
71	Reversal of the Thrombin Generation Inhibitory Effect of Apixaban, Betrixaban, Edoxaban and Rivaroxaban by Andexanet Alpha may be Associated with Increased Thrombogenesis. <i>FASEB Journal</i> , 2019, 33, 515.1.	0.2	0
72	Biomarkers of Hemostatic Dysregulation and Inflammation in Lymphoma: Potential Relevance to Thrombogenesis. <i>FASEB Journal</i> , 2019, 33, 250.11.	0.2	0

#	ARTICLE	IF	CITATIONS
73	Differential Effects of Dabigatran, Rivaroxaban, Apixaban, Edoxaban and Betrixaban on Fibrinokinetics and their Modulation by FEIBA. <i>FASEB Journal</i> , 2019, 33, 819.13.	0.2	0
74	Potency Adjusted Bovine Heparin is Comparable to Porcine Heparin in Patients Undergoing Open Heart Surgery. <i>FASEB Journal</i> , 2019, 33, 819.8.	0.2	0
75	Andexanet Alpha Differentially Neutralizes the Anticoagulant, Antiprotease and Thrombin Generation Inhibitory Effects of Unfractionated Heparin, Enoxaparin and Fondaparinux. <i>Blood</i> , 2019, 134, 1158-1158.	0.6	1
76	Bovine Heparin Demonstrates the Same Interaction with HIT Antibodies As Porcine Heparin. <i>Blood</i> , 2019, 134, 2351-2351.	0.6	0
77	Prothrombinase Induced Clotting Time Is More Sensitive than aPTT and PT and Can be Used for the Monitoring of Anti-Xa Agents in Whole Blood and Plasma. <i>Blood</i> , 2019, 134, 3374-3374.	0.6	0
78	Biomarkers of Hemostatic Dysregulation and Inflammation in Lymphoma: Potential Relevance to Thrombogenesis. <i>Blood</i> , 2019, 134, 4945-4945.	0.6	4
79	USP Potency Adjusted Bovine Mucosal Heparins (BMH) Are Comparable to Porcine Mucosal Heparin (PMH) at Equivalent Levels. <i>Blood</i> , 2019, 134, 165-165.	0.6	1
80	Potency Equated Porcine and Bovine Mucosal Heparin Are Bioequivalent in Terms of Biochemical and Pharmacological Effects. <i>Blood</i> , 2019, 134, 3665-3665.	0.6	1
81	Dysregulation of Hemostatic Biomarkers, Inflammatory Biomarkers, and Alteration of Cellular Indices As Predictors of Adverse Outcomes in Pulmonary Embolism Patients. <i>Blood</i> , 2019, 134, 2408-2408.	0.6	0
82	Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban By Andexanet Alfa As Measured By Whole Blood Thromboelastographic Analysis. <i>Blood</i> , 2019, 134, 1155-1155.	0.6	0
83	Fibrinolytic Deficit and Platelet Activation in Atrial Fibrillation and Their Postablation Modulation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 803-807.	0.7	6
84	Pharmacological Differentiation of Thrombomodulin Alfa and Activated Protein C on Coagulation and Fibrinolysis In Vitro. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 859-866.	0.7	5
85	Inflammatory Biomarker Profiling in Total Joint Arthroplasty and Its Relevance to Circulating Levels of Lubricin, a Novel Proteoglycan. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 950-959.	0.7	12
86	Postoperative Changes in the Systemic Inflammatory Milieu in Older Surgical Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 583-588.	0.7	6
87	Identification of Novel Hemostatic Biomarkers of Adverse Clinical Events in Patients Implanted With a Continuous-Flow Left Ventricular Assist Device. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 965-972.	0.7	8
88	Biomarkers of Inflammation, Thrombogenesis, and Collagen Turnover in Patients With Atrial Fibrillation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 718-723.	0.7	22
89	Synthetic, organic compound vepoloxamer (P-188) potentiates tissue plasminogen activator. <i>Journal of Vascular Surgery</i> , 2018, 67, 294-299.	0.6	4
90	Biomarker Profile of Sepsis-Associated Coagulopathy Using Biochip Assay for Inflammatory Cytokines. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 625-632.	0.7	25

#	ARTICLE	IF	CITATIONS
91	Levels of Matrix-Degrading Enzymes and Lubricin in Patients With Degenerative Joint Disease Requiring Arthroplasty. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 41-46.	0.7	5
92	Biomarkers of Endothelial, Renal, and Platelet Dysfunction in Stage 5 Chronic Kidney Disease Hemodialysis Patients With Heart Failure. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 235-240.	0.7	18
93	Elevated extracellular nucleosomes and their relevance to inflammation in stage 5 chronic kidney disease. <i>International Angiology</i> , 2018, 37, 419-426.	0.4	4
94	FP327ELEVATED LEVELS OF EXTRACELLULAR NUCLEOSOMES, BIOMARKERS OF CELL DEATH, IN STAGE 5 CHRONIC KIDNEY HEMODIALYSIS (CKD5-HD) ARE INDEPENDENT OF CIRCULATING TISSUE FACTOR MICROPARTICLE COMPLEX. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i140-i141.	0.4	0
95	SP272PROFILING OF NEUROVASCULAR DISEASES IN PATIENTS WITH STAGE 5 CHRONIC KIDNEY DISEASE USING SPECIFIC BIOMARKER PROFILING. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i435-i435.	0.4	0
96	Circulating Biomarker Levels in Patients With Stage 5 Chronic Kidney Disease With Respect to Neurovascular Diseases. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 314S-322S.	0.7	0
97	Biomarker Profiling of Neurovascular Diseases in Patients with Stage 5 Chronic Kidney Disease. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 248S-254S.	0.7	0
98	International Normalized Ratio Relevance to the Observed Coagulation Abnormalities in Warfarin Treatment and Disseminated Intravascular Coagulation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 1033-1041.	0.7	8
99	Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 8S-28S.	0.7	114
100	Biomarker Profiling in Stage 5 Chronic Kidney Disease Identifies the Relationship between Angiotensin-2 and Atrial Fibrillation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 269S-276S.	0.7	8
101	Angiotensin 2 Levels in the Risk Stratification and Mortality Outcome Prediction of Sepsis-Associated Coagulopathy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 1223-1233.	0.7	18
102	Bovine Mucosal Heparins Are Comparable to Porcine Mucosal Heparin at USP Potency Adjusted Levels. <i>Frontiers in Medicine</i> , 2018, 5, 360.	1.2	15
103	Relative Neutralization of Heparin from Different Origins by Protamine, Polybrene, Platelet Factor 4, and synthetic heparin antagonist PMX. <i>FASEB Journal</i> , 2018, 32, 570.8.	0.2	0
104	Relationship of Markers of Inflammation, Infection and Endothelial Function to Mortality and Severity of Coagulopathy in Patients with Sepsis-Associated DIC. <i>Blood</i> , 2018, 132, 2495-2495.	0.6	0
105	Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum. <i>Blood</i> , 2018, 132, 2520-2520.	0.6	1
106	Symptom Duration Is Positively Correlated with Factor XIIIa Activity in Acute Pulmonary Embolism. <i>Blood</i> , 2018, 132, 5047-5047.	0.6	0
107	Decreased Thrombin Generation Potential Is Associated with Increased Thrombin Generation Markers in Sepsis Associated Coagulopathy. <i>Blood</i> , 2018, 132, 2505-2505.	0.6	0
108	Development of an Algorithm to Predict Mortality in Patients with Sepsis and Coagulopathy. <i>Blood</i> , 2018, 132, 3791-3791.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Comparison of Low-Molecular-Weight Heparins Prepared From Bovine Heparins With Enoxaparin. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 542-553.	0.7	21
110	Inflammatory and Metabolic Syndrome Biomarker Analysis of Vascular Outcomes in End-stage Renal Disease. <i>International Journal of Angiology</i> , 2017, 26, 043-048.	0.2	5
111	Dysregulation of Tissue Factor, Thrombin-Activatable Fibrinolysis Inhibitor, and Fibrinogen in Patients Undergoing Total Joint Arthroplasty. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 967-972.	0.7	11
112	Synthetic oligosaccharides can replace animal-sourced low-molecular weight heparins. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	82
113	Betrixaban for VTE Prevention in the Medically Ill Population, the APEX Trial: Good News for This Needy Population?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 701-702.	0.7	3
114	Recombinant Factor VIIa-Mediated Activation of Prothrombin Complex Concentrates. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 211-220.	0.7	1
115	The Protective Effect of Poloxamer-188 on Platelet Functions. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 987-991.	0.7	3
116	Modulation of Interleukins in Sepsis-Associated Clotting Disorders. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 34-39.	0.7	3
117	Biomarker profiling of plasma samples utilizing RANDOX biochip array technology. <i>International Angiology</i> , 2017, 36, 499-504.	0.4	8
118	Prevalence of metabolic syndrome in patients undergoing total joint arthroplasty and relevance of biomarkers. <i>International Angiology</i> , 2017, 36, 136-144.	0.4	4
119	Increased Level of Thrombotic Biomarkers in Patients with Atrial Fibrillation Despite Traditional and New Anticoagulant Therapy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 743-748.	0.7	14
120	Analysis of Heparins Derived From Bovine Tissues and Comparison to Porcine Intestinal Heparins. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 520-527.	0.7	41
121	Are Inflammatory Biomarkers Increased in Varicose Vein Blood?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 656-664.	0.7	41
122	Levels of Matrix Metalloproteinases in Arthroplasty Patients and Their Correlation With Inflammatory and Thrombotic Activation Processes. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 441-446.	0.7	9
123	Inflammation and Hemostatic Activation may Contribute to Postsurgical Thrombosis in Patients With Bladder Cancer. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 314-321.	0.7	3
124	Perioperative Factors and Their Effect on the Fibrinolytic System in Arthroplasty Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 274-279.	0.7	10
125	Fibrinolytic Dysregulation in Total Joint Arthroplasty Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 372-376.	0.7	9
126	Comparison of Ufh and Enoxaparin Originated from Bovine, Ovine and Porcine Mucosa with Functional Coagulation Assays. <i>Blood</i> , 2016, 128, 5020-5020.	0.6	3

#	ARTICLE	IF	CITATIONS
127	Porcine and Ovine Mucosal Heparins and Their Depolymerized Derivatives Are Comparable in Contrast to Their Bovine Equivalents. <i>Blood</i> , 2016, 128, 5027-5027.	0.6	1
128	Persistent Prothrombotic State in Atrial Fibrillation Despite Use of Novel Oral Anti-Coagulants. <i>Blood</i> , 2016, 128, 3832-3832.	0.6	0
129	Comparative Studies on the Anticoagulant Actions of Recombinant Thrombomodulin and Heparin and Their Neutralization By FEIBA As Measured By Thromboelastography. <i>Blood</i> , 2016, 128, 2608-2608.	0.6	1
130	International Normalized Ratio Relevance to the Observed Coagulation Abnormalities in Warfarin Treated and Those with Disseminated Intravascular Coagulation. <i>Blood</i> , 2016, 128, 3797-3797.	0.6	0
131	Idarucizumab, a Specific Antidote for Dabigatran, Cross-React with Melagatran and May Also Interact with Other Benzamidine-Containing Compounds. <i>Blood</i> , 2016, 128, 3836-3836.	0.6	0
132	Comparative Anticoagulant Effects of Recombinant Thrombomodulin, Antithrombin, and Unfractionated Heparin, Hematological Implications. <i>Blood</i> , 2016, 128, 4974-4974.	0.6	0
133	Dabigatran Neutralizing Antibody, Idarucizumab, Exhibits Procoagulant and Platelet Activation Responses in Whole Blood. Potential Clinical Implications. <i>Blood</i> , 2016, 128, 2622-2622.	0.6	0
134	Biomarkers of Inflammation and Infection in Sepsis Associated Disseminated Intravascular Coagulation and Their Prognostic Role. <i>Blood</i> , 2016, 128, 1412-1412.	0.6	1
135	Platelet Activation in End-Stage Renal Disease Is Mediated By Extracellular Nucleosomes That Originate from White Blood Cells. <i>Blood</i> , 2016, 128, 4909-4909.	0.6	0
136	Identification & Characterization of Novel Hemostatic Biomarkers of Adverse Clinical Events in Patients with Continuous Flow Left Ventricular Assist Device Implants. <i>Blood</i> , 2016, 128, 4997-4997.	0.6	0
137	Increased Extracellular Nucleosome Levels and Microparticles in Atrial Fibrillation Patients Compared to the Age-Matched Normal Population. <i>Blood</i> , 2016, 128, 4912-4912.	0.6	0
138	Immunoenzymatic and Biochip Array Profiling of the Biomarkers of Inflammation and Hemostatic Activation Processes in ESRD. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2015, 21, 405-411.	0.7	2
139	Pre-Existence of Prothrombotic State in Patients with Atrial Fibrillation Despite Therapy with New and Traditional Anti-Coagulant Drugs. <i>Blood</i> , 2015, 126, 4731-4731.	0.6	1
140	Resourcing of Heparin and Low Molecular Weight Heparins from Bovine, Ovine, and Porcine Origin. Studies to Demonstrate the Biosimilarities. <i>Blood</i> , 2015, 126, 4733-4733.	0.6	8
141	Prevalence of Metabolic Syndrome in Patients with End Stage Renal Disease and Relevance of Biomarkers. <i>FASEB Journal</i> , 2015, 29, 763.4.	0.2	1
142	Increased Biomarkers of Metabolic Syndrome in Total Joint Arthroplasty Patients. <i>FASEB Journal</i> , 2015, 29, 766.8.	0.2	0
143	Dilute Russell's Viper Venom Clotting Time (DRVVT) is Useful for the Routine Monitoring of Newer Non-vitamin K Anticoagulants. <i>FASEB Journal</i> , 2015, 29, 609.9.	0.2	0
144	Comparative Studies on the Molecular and Functional Profile of Sheep Mucosal Derived Enoxaparin. <i>FASEB Journal</i> , 2015, 29, 927.7.	0.2	0

#	ARTICLE	IF	CITATIONS
145	Thrombomodulin Inhibits Tissue factor Mediated Thrombin Generation in blood and Prothrombin Complex Concentrates. FASEB Journal, 2015, 29, 609.11.	0.2	0
146	Bovine and Porcine Mucosal Heparins Exhibit Similar Biologic Profiles. FASEB Journal, 2015, 29, 610.4.	0.2	0
147	Effect of Recombinant Lubricin on Coagulation Parameters in Human Blood. FASEB Journal, 2015, 29, 609.8.	0.2	0
148	Metabolic syndrome marker profile in patients with hepatocellular carcinoma HCC.. Journal of Clinical Oncology, 2015, 33, e22255-e22255.	0.8	0
149	A Generic Version of Recombinant FVIIa Is Similar to the Branded Product (NovoSeven). Blood, 2015, 126, 4746-4746.	0.6	0
150	Role of Platelet Activation in the Pathogenesis of Heart Failure in End-Stage Renal Disease Patients. Blood, 2015, 126, 4636-4636.	0.6	0
151	Upregulation of Microparticles, Tissue Factor, Adhesion Molecules, Nitric Oxide and Adiponectin in End Stage Renal Disease. Blood, 2015, 126, 2312-2312.	0.6	0
152	Functional Protection of Platelets By Tri-Block Polymer (Poloxamer-188) As Studied in Agonist Induced Platelet Aggregation Systems. Blood, 2015, 126, 1037-1037.	0.6	0
153	The Potential Role of Ferritin in Relation to Inflammatory and Metabolic Syndrome Biomarkers in Patients Undergoing Total Joint Arthroplasty of the Hip or Knee. Blood, 2015, 126, 4560-4560.	0.6	0
154	Recombinant Thrombomodulin Inhibits Tissue Factor Mediated Thrombin Generation in Blood Plasma and Is Modulated By Prothrombin Complex Concentrates. Blood, 2015, 126, 2303-2303.	0.6	0
155	Cellular and Functional Characterization of Microparticles in Sepsis-Associated Coagulopathy. Blood, 2015, 126, 2297-2297.	0.6	0
156	Baseline Thrombin Generation Markers and Functional Antithrombin Levels in Sepsis Associated Coagulopathies Are Predictive of the Severity of Pathogenesis. Blood, 2015, 126, 4693-4693.	0.6	0
157	Biomarkers of Hemostatic Dysregulation, Inflammation, and Infection in Patients Diagnosed with Sepsis Associated Coagulopathy. Blood, 2015, 126, 2281-2281.	0.6	1
158	Sustained Release of Tissue Factor Following Thrombosis of Lower Limb Trauma. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 678-686.	0.7	9
159	Social Determinants and Heat Shock Protein-70 Among African American and Non-Hispanic White Women With Atherosclerosis. Biological Research for Nursing, 2014, 16, 258-265.	1.0	9
160	Comparative Biochemical and Functional Studies on a Branded Human Recombinant Factor VIIa and a Biosimilar Equivalent Product. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 565-572.	0.7	6
161	Procoagulant Actions of Circulating Microparticles in Sickle Cell Anemia and Sepsis Associated Coagulopathy and Their Modulation By a Triblock Polymer MST 188. Blood, 2014, 124, 2816-2816.	0.6	1
162	Drug Interactions of Newer Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban with Routinely Used Nonanticoagulant/Antiplatelet Drugs. Blood, 2014, 124, 4267-4267.	0.6	6

#	ARTICLE	IF	CITATIONS
163	Circulating Levels of Rivaroxaban Provide Different Results in Different Clot Based and Amidolytic Assays. a Study on Patients Treated with Two Different Dosages of Rivaroxaban. Blood, 2014, 124, 5084-5084.	0.6	1
164	Usefulness of Dilute Russell's Viper Venom Clotting Time (DRVVT) for the Routine Monitoring of New Oral Anticoagulants. Blood, 2014, 124, 1537-1537.	0.6	0
165	Validation Studies on Coagulation Laboratory Assays Useful for Assessing the Plasma Levels of Apixaban. Blood, 2014, 124, 2866-2866.	0.6	0
166	Recombinant Factor VIIa (rFVIIa) Mediated Activation of Prothrombin Complex Concentrates (PCCs). Studies on the Comparison of Novoseven with a Biosimilar Product. Blood, 2014, 124, 5108-5108.	0.6	0
167	Comparative Studies on Branded Enoxaparin and a US Generic Version of Enoxaparin. Clinical and Applied Thrombosis/Hemostasis, 2013, 19, 261-267.	0.7	6
168	Update on the safety and bioequivalence of biosimilars – focus on enoxaparin. Drug, Healthcare and Patient Safety, 2013, 5, 133.	1.0	26
169	Immune-Mediated Activation Of Coagulation In Patients With Stevens Johnson Syndrome/Toxic Epidermal Necrolysis. Blood, 2013, 122, 1117-1117.	0.6	1
170	Effect Of Dabigatran and Rivaroxiban On Thrombomodulin Mediated Activation Of Protein C and Thrombin Activated Fibrinolysis Inhibitor (TAFI). Potential Clinical Implications. Blood, 2013, 122, 3641-3641.	0.6	3
171	Effect Of Purified Poloxamer 188 And Various Dextrans On Erythrocyte Sedimentation Rate In Healthy Subjects and Patients With Sickle Cell Disease. Blood, 2013, 122, 4764-4764.	0.6	2
172	Defibrotide Interaction With Newer Oral Anticoagulant and Antiplatelet Drugs. Blood, 2013, 122, 4804-4804.	0.6	2
173	Biochemical and pharmacological differentiation of dabigatran, apixaban and rivaroxaban. FASEB Journal, 2013, 27, lb504.	0.2	0
174	Comparative hemmorrhagic studies on dabigatran, apixaban and rivaroxaban in a rat tail bleeding model. FASEB Journal, 2013, 27, lb505.	0.2	0
175	Compositional differences in commercial available prothrombin complex concentrates and their activation by tissue factor. FASEB Journal, 2013, 27, 871.1.	0.2	0
176	A Comparison Of Hemostatic and Inflammatory Markers In Overt and Non-Overt DIC. Blood, 2013, 122, 3577-3577.	0.6	0
177	Increased Levels Of Tissue Factor, Adhesion Molecules, Nitric Oxide and Adiponectin In End Stage Renal Disease. A Complex Interplay. Blood, 2013, 122, 4742-4742.	0.6	0
178	Thrombotic Biomarker Profiling Of Plasma Samples From Patients Undergoing Bypass Surgery Using Protein Chip Array. Blood, 2013, 122, 3579-3579.	0.6	0
179	Dysregulation Of Thrombotic and Hemostatic Factors In End Stage Renal Disease. Blood, 2013, 122, 4793-4793.	0.6	0
180	Oral Anti-Factor Xa and Factor IIa Agent Mediated Inhibition Of Tissue-Factor Mediated Generation Of Thrombin In Prothrombin Complex Concentrates. Blood, 2013, 122, 4810-4810.	0.6	0

#	ARTICLE	IF	CITATIONS
181	Prothrombinase Induced Clotting Time (PICT) and Commercially Available Diluted Russell's Viper Venom Times For The Monitoring Of New Oral Anticoagulants. <i>Blood</i> , 2013, 122, 3642-3642.	0.6	1
182	Comparative Studies Of Purified Poloxamer 188 Using ClotBased and Viscoelastic Measurements Of Coagulation. <i>Blood</i> , 2013, 122, 4770-4770.	0.6	0
183	Gender-based differences in hemostatic responses. <i>Personalized Medicine</i> , 2012, 9, 191-199.	0.8	1
184	A Comparison of the Pharmacodynamic Behavior of Branded and Biosimilar Enoxaparin in Primates. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2012, 18, 294-298.	0.7	8
185	Comparative Antithrombotic and Bleeding Effects of Two U.S. Generic Enoxaparins. <i>Blood</i> , 2012, 120, 1172-1172.	0.6	1
186	Dysregulation of Inflammatory and Hemostatic Markers in Sepsis Associated Disseminated Intravascular Coagulation.. <i>Blood</i> , 2012, 120, 2223-2223.	0.6	1
187	Effect of Heparin and Its Derivatives On the Progression of Tumor Growth in Mouse Lewis Lung Carcinoma Model.. <i>Blood</i> , 2012, 120, 2274-2274.	0.6	1
188	A Randomized, Double-Blind, Placebo-Controlled, Phase-2B Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients with Sepsis and Suspected Disseminated Intravascular Coagulation. <i>Blood</i> , 2012, 120, 24-24.	0.6	2
189	Biomarker Profiling of Bladder Cancer Patients Undergoing Radical Cystectomy. Relevance of Thrombotic and Inflammatory Processes. <i>Blood</i> , 2012, 120, 3405-3405.	0.6	1
190	Compositional Differences in Commercially Available Prothrombin Complex Concentrates. <i>Blood</i> , 2012, 120, 4391-4391.	0.6	7
191	Biomarker profiling of bladder cancer patients undergoing radical cystectomy: Relevance of thrombotic and inflammatory processes.. <i>Journal of Clinical Oncology</i> , 2012, 30, e15008-e15008.	0.8	1
192	Non-antithrombin affinity Semuloparin and it's component oligosaccharides release endogenous TFPI in a molecular weight dependent fashion. <i>FASEB Journal</i> , 2012, 26, 832.5.	0.2	0
193	Tissue factor mediated generation of thrombin in prothrombin complexes is inhibited by anti-Xa based parenteral and oral agents but not by parenteral and oral antithrombin agents. Results from proteomic profiling using protein chip arrays. <i>FASEB Journal</i> , 2012, 26, 1b537.	0.2	0
194	Evaluation of the Antithrombotic and Hemorrhagic Effects of a Novel Ultra Low Molecular Weight Heparin (ULMWH). <i>FASEB Journal</i> , 2012, 26, 832.3.	0.2	0
195	Effect of Dabigatran and Rivaroxaban on thrombomodulin mediated activation of protein C and thrombin activated fibrinolysis inhibitor (TAFI). <i>FASEB Journal</i> , 2012, 26, 832.7.	0.2	2
196	Comparative studies on the effect of newer oral anticoagulants on platelet aggregation. Pharmacological and developmental implications. <i>FASEB Journal</i> , 2012, 26, 1b497.	0.2	0
197	Further Studies on the Isolation and Characterization of Heparin Contaminants Isolated From Recalled Batches of Unfractionated Heparin. <i>FASEB Journal</i> , 2012, 26, 1115.18.	0.2	0
198	Despite Pharmaceutical Equivalence, Generic Versions of Enoxaparin May Differ in Their Pharmacodynamic Actions. Potential Clinical Implications. <i>FASEB Journal</i> , 2012, 26, 832.6.	0.2	0

#	ARTICLE	IF	CITATIONS
199	The effect of tissue factor pathway inhibitor release and interactions with growth factors on the antitumor effects of ultra low molecular weight heparin semuloparin.. Journal of Clinical Oncology, 2012, 30, e13117-e13117.	0.8	0
200	Benign cystic ovarian neoplasms and procoagulant potential.. Journal of Clinical Oncology, 2012, 30, e15538-e15538.	0.8	0
201	Effect of heparin and its derivatives on the progression of tumor growth in mouse Lewis lung carcinoma model.. Journal of Clinical Oncology, 2012, 30, e13115-e13115.	0.8	0
202	Variations in the Circulating Heparin Levels During Maintenance Hemodialysis in End Stage Renal Disease Patients. Blood, 2012, 120, 3412-3412.	0.6	0
203	Comparative Studies On Branded Enoxaparin and a US Generic Version of Enoxaparin.. Blood, 2012, 120, 2264-2264.	0.6	0
204	Validation of the Use of Apixaban As an Alternate Anticoagulant for the Management of Patients with Heparin-Induced Thrombocytopenia.. Blood, 2012, 120, 2265-2265.	0.6	0
205	Population Based Differences in the Anticoagulant and Antiprotease Responses of Newer and Oral Anticoagulant Drugs. Blood, 2012, 120, 3421-3421.	0.6	0
206	Defibrotide Interactions with Newer Oral Anticoagulants and Antithrombotic Agents. Blood, 2012, 120, 3411-3411.	0.6	0
207	Thrombin Generation Mediators and Markers in Sepsis Associated Coagulopathy and Their Modulation by Recombinant Thrombomodulin. Blood, 2012, 120, 1131-1131.	0.6	0
208	Tissue Factor Mediated Activation of Prothrombin Complex Concentrates (PCCs) Is Differently Inhibited by Dabigatran, Rivaroxaban and Apixaban. Potential Clinical Implications. Blood, 2012, 120, 3410-3410.	0.6	1
209	An Open Label, Non-randomized, Prospective Clinical Trial Evaluating the Immunogenicity of Branded Enoxaparin Versus Biosimilars in Healthy Volunteers. Clinical and Applied Thrombosis/Hemostasis, 2011, 17, 66-69.	0.7	8
210	Protein Chip Array Profiling of Molecular Variants of Hirudins Using Surface Enhanced Laser Desorption Ionization (SELDI) Technique. FASEB Journal, 2011, 25, 1002.18.	0.2	0
211	Increased prevalence of Anti-Heparin Platelet factor 4 antibodies in patients with sepsis associated Disseminated Intravascular Coagulation. FASEB Journal, 2011, 25, 1002.1.	0.2	0
212	Cross-Reactivity of Rabbit Anti-Bovine Thrombin IgGs with a Human Plasma Derived Thrombin Preparation (Evithrom [®]). FASEB Journal, 2010, 24, 951.11.	0.2	0
213	Potency Adjustment of Unfractionated Heparins to Harmonize the USP and WHO Standardization. Impact on Anticoagulant Practice in the US. FASEB Journal, 2010, 24, 951.8.	0.2	0
214	Biochip Array Analysis of Various Mediators of Inflammation in Disseminated Intravascular Coagulation. FASEB Journal, 2010, 24, 951.4.	0.2	0
215	Comparative Studies on Branded Dalteparin with Two Generic Versions: Hepagumin and Fluzepamin. FASEB Journal, 2010, 24, 951.7.	0.2	0
216	Quantification of von Willebrand Factor and von Willebrand Factor Propeptide in Patients with End Stage Renal Disease. FASEB Journal, 2010, 24, 1030.4.	0.2	0

#	ARTICLE	IF	CITATIONS
217	Baseline and Serial Microparticle Concentration Analysis in Elderly Patients with Acute Hip Fracture Treated with Heparins. FASEB Journal, 2010, 24, lb430.	0.2	0
218	Elevated Levels of Circulating Microparticles in Disseminated Intravascular Coagulation and Their Impact on the Inflammatory Process. FASEB Journal, 2010, 24, 951.13.	0.2	0
219	Prolonged Administration of Defibrotide Is Non-Immunogenic in Rats and Dogs.. Blood, 2009, 114, 4180-4180.	0.6	1
220	Bioavailability of oversulfated chondroitin sulfate in rats. Pharmacological implications in contaminated heparins. FASEB Journal, 2009, 23, LB401.	0.2	0
221	Biomarker profiling in elderly patients with acute hip fracture: modulation by prophylactic dosage of enoxaparin. FASEB Journal, 2009, 23, 569.1.	0.2	0
222	Species variation in the heparin contaminant mediated generation of kallikrein. FASEB Journal, 2009, 23, 569.14.	0.2	0
223	Generic versions of argatroban can be differentiated from branded argatroban using a thrombin generation assay (TGA). FASEB Journal, 2009, 23, 575.1.	0.2	0
224	Neutralization of Hemorrhagic and Antithrombotic Activities of Heparins by a Novel Salicylamide Derivative. FASEB Journal, 2009, 23, 569.6.	0.2	1
225	Differential thrombin generation inhibition by branded and generic low molecular weight heparins (LMWHs) as studied using a fluorescence substrate based kinetic method. FASEB Journal, 2009, 23, 569.3.	0.2	0
226	Differential augmentation of the anticoagulant responses by newly developed oral anti-Xa and anti-IIa drugs in patients with liver disease. FASEB Journal, 2009, 23, LB383.	0.2	0
227	Decreased Immunogenicity of Purified Topical Bovine Thrombin Preparations.. Blood, 2009, 114, 4209-4209.	0.6	2
228	Oversulfated Chondroitin Sulfate Does Not Cause Augmentation in HIT Antibody Mediated Heparin-Induced Platelet Aggregation (HIPA).. Blood, 2009, 114, 2417-2417.	0.6	19
229	Gender-Based Differences in Hemostatic Responses. Implications in Effective Anticoagulant Management.. Blood, 2009, 114, 2103-2103.	0.6	0
230	Persistent Inhibition of Thrombin Generation After Intravenous Administration of Enoxaparin in Primates.. Blood, 2009, 114, 2095-2095.	0.6	0
231	Pharmacodynamic Differences of An Anti-Xa Enriched Low Molecular Weight Heparin, AVE 5026 in Comparison to Enoxaparin and Unfractionated Heparin.. Blood, 2009, 114, 4171-4171.	0.6	0
232	Cross-Reactivity of Rabbit Anti-Bovine Thrombin IgGs with Human β -Thrombin and a Recombinant Version of Human Thrombin (Recothrom β).. Blood, 2009, 114, 4211-4211.	0.6	0
233	Prevalence of Anti-Heparin Platelet Factor 4 Antibodies in Patients with Disseminated Intravascular Coagulation.. Blood, 2009, 114, 2094-2094.	0.6	0
234	Protease Generation by Chondroitin Sulfate, Semisynthetic OSCS Preparations and Contaminants Isolated From Heparin.. Blood, 2009, 114, 3133-3133.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Comparative Studies On Heparin Contaminant Interactions with Normals, Liver Disease, Heparin Treated and Oral Anticoagulant Treated Patients Plasma.. Blood, 2009, 114, 2093-2093.	0.6	0
236	Oversulfated Chondroitin Sulfate Is Not the Sole Contaminant in Recalled Heparin Preparations.. Blood, 2009, 114, 1070-1070.	0.6	0
237	Contaminants Isolated From Recalled Heparin Are Not All the Same: Clinical Implications.. Blood, 2009, 114, 1069-1069.	0.6	0
238	Defibrotide Interactions with Anticoagulant Drugs. Developmental Implications.. FASEB Journal, 2008, 22, 1118.12.	0.2	0
239	Differential Prevalence of Anti-Heparin PF4 Immunoglobulin Subtypes in Patients Treated with Reviparin, Enoxaparin, and Certoparin. Implications in HIT Pathogenesis.. FASEB Journal, 2008, 22, 1118.13.	0.2	0
240	Pharmacokinetics of Defibrotide in Non-Human Primates is Dose Dependent.. FASEB Journal, 2008, 22, 1118.11.	0.2	0
241	Neutralization of Unfractionated Heparin and Low Molecular Weight Heparin by Novel Salicylamide Derivatives. FASEB Journal, 2008, 22, 1118.5.	0.2	0
242	Neutralization of the Anticoagulant and Anti-Xa Effects of Fondaparinux and Idraparinux by a Novel Synthetic Antagonist. Pharmacologic Implications. FASEB Journal, 2008, 22, .	0.2	1
243	Comparative Anticoagulant Effects of Suledoxide and Enoxaparin in Citrated Whole Blood. FASEB Journal, 2008, 22, 1118.8.	0.2	0
244	Effect of Heparin and Low Molecular Weight Heparin on the Regulation of Microparticle in Atrial Fibrillation. FASEB Journal, 2008, 22, 1118.3.	0.2	0
245	Differential Interaction of Anti-heparin Platelet Factor 4 Antibodies with Branded and Generic Versions of Low Molecular Weight Heparins. Pathophysiologic and Bioequivalence Implications.. FASEB Journal, 2008, 22, 1118.4.	0.2	0
246	Molecular Profiling of Generic Versions of the Low Molecular Weight Heparin Enoxaparin and Their Digestion by Heparinase.. FASEB Journal, 2008, 22, 1118.6.	0.2	0
247	AVE5026: A New Hemisynthetic Ultra Low Molecular Weight Heparin with Enriched Anti-Xa Activity and Enhanced Antithrombotic Activity for Management of Cancer Associated Thrombosis. Blood, 2008, 112, 4046-4046.	0.6	0
248	Increased Levels of Anaphylatoxin (C5a) and Bradykinin in End-Stage Renal Disease Patients on Maintenance Hemodialysis. Potential Relevance to Heparin Mediated Hemodynamic Responses. Blood, 2008, 112, 4079-4079.	0.6	0
249	In Vivo Neutralization of Unfractionated Heparin and Low Molecular Weight Heparin by a Novel Salicylamide Derivative.. Blood, 2008, 112, 1825-1825.	0.6	0
250	Defibrotide Augments the Anticoagulant Actions of Heparin and Low Molecular Weight Heparins. Blood, 2008, 112, 4086-4086.	0.6	0
251	Pharmacoequivalence of Enoxaparin and Contaminated Enoxaparin. Blood, 2008, 112, 3018-3018.	0.6	0
252	Increased Procalcitonin Levels in End Stage Renal Disease and Chronic Kidney Disease as An Indicator of Inflammatory Activation. Blood, 2008, 112, 5472-5472.	0.6	0

#	ARTICLE	IF	CITATIONS
253	Fibrinokinetic Deficit in Chronic Kidney Disease and End Stage Renal Disease Patients Contributes to the Hemostatic Abnormalities. <i>Blood</i> , 2008, 112, 4078-4078.	0.6	0
254	Increased Antithrombotic and Bleeding Effects of Contaminated Heparins; Hematological Implications. <i>Blood</i> , 2008, 112, 3021-3021.	0.6	0
255	Selective Serotonin Reuptake Inhibitors Influence Agonist-Induced Platelet Aggregation. Preliminary Results from Comorbidity of Depression and Cardiovascular Disease Study. <i>Blood</i> , 2008, 112, 4556-4556.	0.6	0
256	Molecular and Functional Heterogeneity in Contaminants Isolated from Recalled Heparin. Impact on Anticoagulation and Potential Adverse Reactions. <i>Blood</i> , 2008, 112, 4048-4048.	0.6	4
257	Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. <i>Thrombosis Research</i> , 2007, 119, 653-661.	0.8	20
258	Argatroban is Capable of Passing Through the Blood Brain Barrier. Potential Implications in the Management of Thrombotic Stroke. <i>FASEB Journal</i> , 2007, 21, A397.	0.2	1
259	Hemodialysis Mediated Upregulation of Myeloperoxidase in End Stage Renal Disease: Pathophysiologic Implications. <i>FASEB Journal</i> , 2007, 21, A438.	0.2	2
260	Pharmacodynamic Differentiation of Generic Low Molecular Weight Heparins.. <i>Blood</i> , 2007, 110, 1871-1871.	0.6	1
261	AVE5026: A Novel, Extractive Heparinoid with Enriched Anti-Xa Activity and Enhanced Antithrombotic Activity.. <i>Blood</i> , 2007, 110, 1881-1881.	0.6	2
262	ProteinChip Array Profiling and Markers of Inflammation and Thrombin Generation in Plasma Samples from Lung Cancer Patients and Their Modulation by Chemotherapy with or without Warfarin Anticoagulation.. <i>Blood</i> , 2007, 110, 3978-3978.	0.6	14
263	Factor Xa Inhibitors Can Be Differentiated in Xa, IIa and Microparticle Generation and Other Whole Blood Based Assays.. <i>Blood</i> , 2007, 110, 931-931.	0.6	1
264	Inhibition of Heparinase I by Defibrotide: Potential Clinical Implications. <i>FASEB Journal</i> , 2007, 21, A1124.	0.2	0
265	Prevalence of Non-specific Cross-reactive Epitopes to Bovine Factor Va Light Chain Fragments in Normal and Patient Plasma. <i>FASEB Journal</i> , 2007, 21, A1124.	0.2	0
266	Antiinflammatory Effects of Argatroban Can Be Differentiated from Other Direct Thrombin Inhibitors. Experimental and Clinical Observations. <i>FASEB Journal</i> , 2007, 21, A1127.	0.2	0
267	A Unique Biomarker Is Associated with the Prevalence of Functional Heparin Induced Thrombocytopenia (HIT) Associated Antibodies: Results from Proteomic (ProteinChip Array) Profiling of ELISA Positive HIT Plasma Samples.. <i>Blood</i> , 2007, 110, 3205-3205.	0.6	0
268	Modulation of Platelet Function by Recombinant Thrombomodulin Hematologic Implications.. <i>Blood</i> , 2007, 110, 3898-3898.	0.6	1
269	Upregulation of Microparticles and CD40 Ligand in Antiphospholipid Syndrome: Potential Implication in Inflammatory Responses and Thrombosis.. <i>Blood</i> , 2007, 110, 1740-1740.	0.6	0
270	Regulation of Microparticles and Adhesion Molecules in Pregnancy. Diagnostic and Pathophysiologic Implications.. <i>Blood</i> , 2007, 110, 1639-1639.	0.6	8

#	ARTICLE	IF	CITATIONS
271	Suppression of Markers of Thrombin Generation and Inflammation in Patients Receiving Low Molecular Weight Heparin Compared to Unfractionated Heparin for TEE-Guided Cardioversion of Atrial Fibrillation.. Blood, 2007, 110, 3621-3621.	0.6	0
272	Potency Adjusted Generic Versions of Argatroban Can Be Differentiated from Branded Argatroban in Thrombin Generation and Platelet Activation Assays.. Blood, 2007, 110, 4007-4007.	0.6	0
273	Methodologic Variations in the Determinations of Anti-Platelet Factor 4-Heparin Antibodies in Patients Suspected of Having Heparin Induced Thrombocytopenia: Diagnostic and Prognostic Implications.. Blood, 2007, 110, 3206-3206.	0.6	0
274	Compositional Differences in the Oligosaccharide Components of Generic Versions of Enoxaparin and Dalteparin.. Blood, 2007, 110, 3999-3999.	0.6	0
275	In Vitro Characterization of the Neutralization of Unfractionated Heparin and Low Molecular Weight Heparin by Novel Salicylamide Derivatives.. Blood, 2007, 110, 1869-1869.	0.6	1
276	Functional Microparticles Are up Regulated in Patients with Anti-Heparin/Platelet Factor 4 Antibodies: A Potential Mechanism of Thrombogenesis in the Heparin-Induced Thrombocytopenia Syndrome.. Blood, 2007, 110, 2105-2105.	0.6	0
277	Coagulation Profiling of Human, Non-human Primate, Pig, Dog, Rabbit, and Rat Plasma: Pharmacologic Implications. FASEB Journal, 2006, 20, A655-A656.	0.2	2
278	Differences in the native and heparinase I digestion profiles of a generic enoxaparin: Pharmacologic implications. FASEB Journal, 2006, 20, LB105.	0.2	0
279	Discordance between the 1st and 2nd low molecular weight heparin (LMWH) standards. Implications for dosing. FASEB Journal, 2006, 20, A656.	0.2	0
280	Hyperhomocysteinemia in Cancer Patients with Thrombosis is Not Associated With Methylene Tetrahydrofolate Reductase Gene Mutations and Can Be Down Regulated by Low Molecular Weight Heparin Treatment. FASEB Journal, 2006, 20, .	0.2	0
281	Are Generic LMWHs Equivalent to the Innovator Products?. FASEB Journal, 2006, 20, A654.	0.2	1
282	Nitric Oxide and Asymmetric Dimethylarginine Levels in Malignancy Associated Thrombosis and Their Modulation by Anticoagulants.. Blood, 2006, 108, 1477-1477.	0.6	0
283	Upregulation of Myeloperoxidase in End Stage Renal Disease and Its Modulation by Hemodialysis. A Paradoxical Paradigm.. Blood, 2006, 108, 3838-3838.	0.6	0
284	Inhibition of Heparinase I by Defibrotide with Potential Clinical Implications.. Blood, 2006, 108, 1626-1626.	0.6	0
285	Discordance between the 1st and 2nd Low Molecular Weight Heparin Standards. Implications for Dosing.. Blood, 2005, 106, 4158-4158.	0.6	0
286	The Oral, Direct Factor Xa Inhibitor BAY 59-7939 Does Not Cross-React with Anti-Heparin/PF4 (Heparin-Induced Thrombocytopenia) Antibodies.. Blood, 2005, 106, 1883-1883.	0.6	2
287	Relative Inhibition of Thrombin Activatable Fibrinolytic Inhibitor by Newly Developed Thrombin Inhibitors: Impact on Bleeding and Antithrombotic Actions.. Blood, 2005, 106, 4051-4051.	0.6	0
288	Von Willebrand Factor Cleaving Protease (ADAMTS-13) Antigen Levels Are Decreased in Patients with Heparin-Induced Thrombocytopenia.. Blood, 2005, 106, 3970-3970.	0.6	4

#	ARTICLE	IF	CITATIONS
289	Synthetic Anti-Xa Drugs Can Be Used for Parenteral Anticoagulation but Not Fondaparinux.. Blood, 2004, 104, 4088-4088.	0.6	8
290	Heparin, low-molecular-weight heparins, and heparin pentasaccharide. Hematology/Oncology Clinics of North America, 2003, 17, 313-341.	0.9	50
291	Hemostatic effects of 1 mg daily warfarin on post CABG patients. Post CABG Studies Investigators. Journal of Thrombosis and Thrombolysis, 1999, 7, 313-318.	1.0	5
292	Low molecular weight heparins: a developmental perspective. Expert Opinion on Investigational Drugs, 1997, 6, 705-733.	1.9	14
293	Low Molecular Weight Heparins. Drugs and Aging, 1992, 2, 406-422.	1.3	11
294	Protein C Antigen Deficiency and Warfarin Necrosis. American Journal of Clinical Pathology, 1986, 86, 653-655.	0.4	64
295	Validity of Serine Protease Inhibition Tests in the Evaluation and Monitoring of the Effect of Heparin and Its Fractions. Seminars in Thrombosis and Hemostasis, 1985, 11, 112-120.	1.5	16
296	In Vitro Evaluation of Heparin Fractions: Old vs. New Methods. CRC Critical Reviews in Clinical Laboratory Sciences, 1985, 22, 361-389.	1.0	22